BioLineRx is trading 5.3% higher at $2.79 in after-hours trading, recovering from a regular-session decline despite no new company-specific filings or news identified.
- The stock closed the regular session down 5.8% at $2.66.
- The move likely reflects thin after-hours liquidity and improved market sentiment rather than a defined corporate event.
- Traders should monitor for any late-breaking regulatory or pipeline updates that may impact the stock.